201 related articles for article (PubMed ID: 29264472)
1. EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.
Araki T; Liu X; Kameda H; Tone Y; Fukuoka H; Tone M; Melmed S
J Endocr Soc; 2017 Feb; 1(2):127-143. PubMed ID: 29264472
[TBL] [Abstract][Full Text] [Related]
2. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
3. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
4. E2F1-mediated human POMC expression in ectopic Cushing's syndrome.
Araki T; Liu NA; Tone Y; Cuevas-Ramos D; Heltsley R; Tone M; Melmed S
Endocr Relat Cancer; 2016 Nov; 23(11):857-870. PubMed ID: 27935805
[TBL] [Abstract][Full Text] [Related]
5. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Liu NA; Jiang H; Ben-Shlomo A; Wawrowsky K; Fan XM; Lin S; Melmed S
Proc Natl Acad Sci U S A; 2011 May; 108(20):8414-9. PubMed ID: 21536883
[TBL] [Abstract][Full Text] [Related]
6. Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship With Tumor Behavior.
Liu X; Feng M; Dai C; Bao X; Deng K; Yao Y; Wang R
Front Endocrinol (Lausanne); 2019; 10():785. PubMed ID: 31798535
[No Abstract] [Full Text] [Related]
7. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
[TBL] [Abstract][Full Text] [Related]
8. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
[TBL] [Abstract][Full Text] [Related]
9. Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.
Hinojosa-Amaya JM; Lam-Chung CE; Cuevas-Ramos D
Front Endocrinol (Lausanne); 2021; 12():657382. PubMed ID: 33986726
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.
Asari Y; Kageyama K; Sugiyama A; Kogawa H; Niioka K; Daimon M
Endocr J; 2019 Jun; 66(6):515-522. PubMed ID: 30880293
[TBL] [Abstract][Full Text] [Related]
11. A human ACTH-secreting corticotroph tumoroid model: Novel Human ACTH-Secreting Tumor Cell in vitro Model.
Zhang D; Hugo W; Redublo P; Miao H; Bergsneider M; Wang MB; Kim W; Yong WH; Heaney AP
EBioMedicine; 2021 Apr; 66():103294. PubMed ID: 33773184
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.
Araki T; Wang J; Lawrence R; Kawakami Y
Endocrinology; 2022 Aug; 163(8):. PubMed ID: 35678423
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of a selective Jak2 inhibitor on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT20 cells.
Asari Y; Kageyama K; Nakada Y; Tasso M; Takayasu S; Niioka K; Ishigame N; Daimon M
Onco Targets Ther; 2017; 10():4329-4338. PubMed ID: 28919782
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
15. Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease.
Du L; Bergsneider M; Mirsadraei L; Young SH; Jonker JW; Downes M; Yong WH; Evans RM; Heaney AP
Proc Natl Acad Sci U S A; 2013 May; 110(21):8555-60. PubMed ID: 23653479
[TBL] [Abstract][Full Text] [Related]
16. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome.
de Keyzer Y; Lenne F; Auzan C; Jégou S; René P; Vaudry H; Kuhn JM; Luton JP; Clauser E; Bertagna X
J Clin Invest; 1996 Mar; 97(5):1311-8. PubMed ID: 8636444
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas.
Pereda MP; Lohrer P; Kovalovsky D; Perez Castro C; Goldberg V; Losa M; Chervín A; Berner S; Molina H; Stalla GK; Renner U; Arzt E
Exp Clin Endocrinol Diabetes; 2000; 108(3):202-7. PubMed ID: 10926317
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth.
Yang Y; Sheng M; Huang F; Bu D; Liu X; Yao Y; Dai C; Sun B; Zhu J; Jiao Y; Wei Z; Zhu H; Lu L; Zhao Y; Jiang C; Wang R
Pituitary; 2014 Dec; 17(6):505-13. PubMed ID: 24379119
[TBL] [Abstract][Full Text] [Related]
19. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
20. [Pathology and pathogenesis of pituitary corticotroph adenoma].
Trouillas J
Neurochirurgie; 2002 May; 48(2-3 Pt 2):149-62. PubMed ID: 12058122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
